![Olaparib / Primary peritoneal carcinoma / Ovarian cancer / BRCA mutation / Fallopian tube cancer / PARP1 / Serous carcinoma / PARP inhibitor / Breast cancer / Medicine / Oncology / Gynaecological cancer Olaparib / Primary peritoneal carcinoma / Ovarian cancer / BRCA mutation / Fallopian tube cancer / PARP1 / Serous carcinoma / PARP inhibitor / Breast cancer / Medicine / Oncology / Gynaecological cancer](/pdf-icon.png)
| Document Date: 2014-12-15 23:44:34 Open Document File Size: 663,68 KBShare Result on Facebook
Company ADP / Gynecological Cancer InterGroup / / Country Australia / / Event FDA Phase / / Facility harbour TP53 / The complex / / IndustryTerm machinery / proposed medical services / therapy for women who have PSR ovarian cancer / / MedicalCondition Epithelial ovarian carcinoma / Ovarian cancer Ovarian cancer / cancers / ovarian cancers / hereditary susceptibility / ovarian cancer / BRCA-related cancers / cancer / platinum-sensitive relapsed ovarian cancer / fallopian tube cancer / disease / PSR ovarian cancer / carcinomas / invasive epithelial ovarian cancer / tumour / primary peritoneal cancer / carcinoma / tumours / / MedicalTreatment chemotherapy / surgery / counselling / / Organization Medicare / / Product carboplatin / adenosine / paclitaxel / NCT00753545 / / Technology genotyping / recombination / high grade serous component Applicant Submitted Proposed Protocol / chemotherapy / / URL http /
SocialTag |